Rhythm Pharmaceuticals (NASDAQ: RYTM)
Rhythm Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Rhythm Pharmaceuticals Company Info
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
News & Analysis
What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022
These three healthcare stocks have defied the 2022 bear market.
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today
The biotech's second-quarter earnings report is a big hit with shareholders.
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
Just because the market abandoned Rhythm Pharmaceuticals, Baidu, and Vista Outdoor doesn't mean you should.
The Smartest People on Wall Street Are Buying These 3 Stocks. Should You Follow?
Three Motley Fool contributors offer second opinions on stocks that are attracting smart money.
Here's Why Rhythm Pharmaceuticals Inc Rose as Much as 37% Today
The biopharma stock is bouncing back after the announcement of a share offering.
This Company Gained 76% in Its IPO -- and It Isn't Even a Tech Company
Investors were excited about the initial public offering of this obesity-drug biotech.
What Happened in the Stock Market Today
On another record day for Wall Street, Constellation Brands rose on earnings and a biotech IPO almost doubled.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.